Cyamemazine
CAS : 3546-03-0
Ref. 3D-FC156977
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté |
Informations sur le produit
- 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine-2-carbonitrile
- 10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile
- 10H-Phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)- (9CI)
- 10H-Phenothiazine-2-carbonitrile, 10-[3-(dimethylamino)-2-methylpropyl]-
- 2-Cyano-10-(3-dimethylamino-2-methylpropyl)phenothiazine
- 7204 R.E.
- 7204 Rp
- Brn 0093261
- Ciamatil
- Ciamemazina
- Voir d'autres synonymes
- Ciamemazina [INN-Spanish]
- Cianatil
- Cyamemazin
- Cyamemazine [INN]
- Cyamemazinum
- Cyamemazinum [INN-Latin]
- Cyamepromazine
- Cyamepromezine
- F.I. 6229
- Fi 6229
- Kyamepromazine
- Phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-
- R.P. 7204
- Rp 7204
- Tercian
- Th 2602
- Unii-A2Jgv5Cnu4
Cyamemazine is a medication used to treat schizophrenia in adults. It is an antipsychotic drug that blocks dopamine receptors, which may help to reduce psychotic symptoms. Cyamemazine belongs to the family of phenothiazines, which are a class of drugs called dopamine receptor blockers. The rate constant for cyamemazine has been determined by analytical methods and found to be 1.3 x 10-4 M-1s-1. Control analysis has also been performed on cyamemazine and shown that it does not interact with 5-HT2C receptors or locomotor activity in rats. Cyamemazine is metabolized by the liver into a variety of metabolites, including one called cyamemazine sulfoxide, which can bind to cardiac tissue and cause cardiotoxicity in humans. Cyamemazine has been shown to have some effects on wastewater treatment, such as the removal of chlorophenols and phthalates from wastewater effluents.